Vivani Medical Inc (VANI)
$1.29
Live
Performance
- $1.27$1.32$1.29
1.85%
Downside
Day's Volatility :4.08%
Upside
2.27%
- $0.84$7.80$1.29
34.88%
Downside
52 Weeks Volatility :89.23%
Upside
83.46%
Returns
| Period | Vivani Medical Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 0.0% | 0.0% |
6 Months | -22.16% | 0.0% |
1 Year | 30.0% | 0.0% |
3 Years | -68.6% | -23.0% |
Highlights
Market Capitalization | 70.7M |
Book Value | $0.43 |
Earnings Per Share (EPS) | -0.46 |
Wall Street Target Price | 8.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -29.29% |
Return On Equity TTM | -86.1% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 130.0K |
EBITDA | -24.9M |
Diluted Eps TTM | -0.46 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | -0.12 |
EPS Estimate Next Quarter | -0.13 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 520.16%
Technicals Summary
Sell
Neutral
Buy
Vivani Medical Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Vivani Medical Inc | 7.44% | -22.16% | 30.0% | -68.6% | -68.6% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Vivani Medical Inc | NA | NA | NA | 0.0 | -0.86 | -0.29 | NA | 0.43 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Vivani Medical Inc | Buy | $70.7M | -68.6% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Vivani Medical Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 52.9%
Institutional Holdings
Sabby Management LLC
3.85%Tanager Wealth Management LLP
2.36%Vanguard Group Inc
1.63%Commonwealth Equity Services Inc
0.60%Geode Capital Management, LLC
0.59%Monetary Management Group Inc
0.35%
Company Information
vivani leverages proprietary technologies to develop and commercialize drug and device implants, including its lead asset npm-119 (exenatide implant), which seeks to treat patients with chronic diseases with high unmet medical need.
Organization | Vivani Medical Inc |
Employees | 36 |
CEO | Mr. Adam Mendelsohn Ph.D. |
Industry | Miscellaneous |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$1.29
-0.77%
Invesco Bulletshares 2025 Hi
$1.29
-0.77%
Schwab International Dividend Equity Etf
$1.29
-0.77%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$1.29
-0.77%
Lightpath Technologies Inc
$1.29
-0.77%
Vaneck Vectors Global Alternative Energy Etf
$1.29
-0.77%
First Trust Flexible Municipal High Income Etf
$1.29
-0.77%
Drx Dly Reg Bank Bull 3x
$1.29
-0.77%
Graniteshares 2x Long Pltr Daily Etf
$1.29
-0.77%